Use of approved Lu ‐177 radiopharmaceuticals in patients with end‐stage renal disease: A review of the literature and proposed treatment algorithm
Journal of Neuroendocrinology · 2024
DOI: 10.1111/jne.13393 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Neuroendocrinology, 2024. Verfasst von Nikolaos A Trikalinos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Lutetium, Neuroendocrine Tumors, Kidney Failure, Chronic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Peptide receptor radionuclide therapy (PRRT) can be a very useful treatment for patients with neuroendocrine neoplasms and metastatic castration‐resistant prostate cancer but it is routinely avoided in those with advanced kidney disease because it can adversely affect the renal function. Accordingly, no clear guidelines exist on the use of PRRT for patients on hemodialysis (HD). We performed a literature review to identify publications on HD patients who received PRRT with Lutetium‐177 (Lu 177 ) Dotatate and Y‐90 and obtained information on Lu 177 pharmacokinetics and early testing data from the manufacturer. We also perused the most recent North American Neuroendocrine Tumor Society (NANETS)/European Neuroendocrine Tumor Society (ENETS) recommendations. Seven relevant publications with a total of 15 patients were included. Patients received dose‐adjusted fractions of PRRT with HD occurring usually within 24 h. There were no immediate or long‐term serious adverse events attributed to the radioligand, although data was limited. Using available evidence and input from a multidisciplinary group, we have created an institutional workflow. Dose‐adjusted PRRT can be offered to patients undergoing HD under careful, multidisciplinary supervision.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
- Intermountain Kidney Services, Intermountain Health, Murray, Utah, USA.
- Office of Radiation Safety, Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of Nuclear Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
ORCID-Profile: Nikolaos A Trikalinos
Zitieren
APA
Trikalinos, N. A., Kim, H., Vijayan, A., Amurao, M., & Prasad, V. (2024). Use of approved Lu ‐177 radiopharmaceuticals in patients with end‐stage renal disease: A review of the literature and proposed treatment algorithm. Journal of Neuroendocrinology. https://doi.org/10.1111/jne.13393
Vancouver
Trikalinos NA, Kim H, Vijayan A, Amurao M, Prasad V. Use of approved Lu ‐177 radiopharmaceuticals in patients with end‐stage renal disease: A review of the literature and proposed treatment algorithm. Journal of Neuroendocrinology. 2024. doi:10.1111/jne.13393
BibTeX
@article{Trikalinos2024,
author = {Trikalinos, Nikolaos A and Kim, Hyun and Vijayan, Anitha and Amurao, Maxwell and Prasad, Vikas},
title = {Use of approved Lu ‐177 radiopharmaceuticals in patients with end‐stage renal disease: A review of the literature and proposed treatment algorithm},
journal = {Journal of Neuroendocrinology},
year = {2024},
doi = {10.1111/jne.13393}
}
EUVIMED